Temporal and brain region‐specific elevations of soluble Amyloid‐β40‐42 in the Ts65Dn mouse model of Down syndrome and Alzheimer’s disease
Sign Up to like & getrecommendations! Published in 2022 at "Aging Cell"
DOI: 10.1111/acel.13590
Abstract: Down syndrome (DS) is a leading cause of intellectual disability that also results in hallmark Alzheimer's disease (AD) pathologies such as amyloid beta (Aβ) plaques and hyperphosphorylated tau. The Ts65Dn mouse model is commonly used… read more here.
Keywords: ts65dn; alzheimer disease; region; model ... See more keywords
Daunorubicin-induced arterial stiffness in Down syndrome
Sign Up to like & getrecommendations! Published in 2023 at "Physiology"
DOI: 10.1152/physiol.2023.38.s1.5733537
Abstract: Children with Down syndrome have a high risk of leukemia and are at a higher risk for delayed early onset heart failure after treatment. Cardiac toxicity is more severe in female patients. Traditional risk factors… read more here.
Keywords: ts65dn mice; ts65dn; daunorubicin; physiology ... See more keywords
Pharmacological Modulation of Three Modalities of CA1 Hippocampal Long-Term Potentiation in the Ts65Dn Mouse Model of Down Syndrome
Sign Up to like & getrecommendations! Published in 2018 at "Neural Plasticity"
DOI: 10.1155/2018/9235796
Abstract: The Ts65Dn mouse is the most studied animal model of Down syndrome. Past research has shown a significant reduction in CA1 hippocampal long-term potentiation (LTP) induced by theta-burst stimulation (TBS), but not in LTP induced… read more here.
Keywords: ltp; ca1 hippocampal; ts65dn mouse; ts65dn ... See more keywords